COMPANY
CuraSen Therapeutics
CuraSen Therapeutics is developing treatments that selectively activate adrenergic receptors (ARs) in the brain. From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 2: A Study in Subjects With Neurogenic Orthostatic Hypotension source ↗
- Trial start Phase 2: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) source ↗
- Trial start Phase 2: A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease source ↗
- Trial start Phase 1: A Study of CST-2032 in Subjects With Cognitive Impairment source ↗
- Trial start Phase 2: A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders source ↗
Clinical trials (lead sponsor) 5
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07089043 | A Study in Subjects With Neurogenic Orthostatic Hypotension | Phase 2 | Active, not recruiting | Sep 12, 2025 | Sep 24, 2026 (actual) |
| NCT05104463 | A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease | Phase 2 | Completed | Apr 11, 2022 | Dec 20, 2023 (actual) |
| NCT04739423 | A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders | Phase 2 | Completed | Jun 28, 2021 | Jul 4, 2022 (actual) |
| NCT04935762 | A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) | Phase 2 | Withdrawn | 2024-06 | 2024-12 (estimated) |
| NCT05033912 | A Study of CST-2032 in Subjects With Cognitive Impairment | Phase 1 | Withdrawn | 2021-10 | 2022-03 (estimated) |